HomeCompareAMRS vs GBDC

AMRS vs GBDC: Dividend Comparison 2026

AMRS yields 4000.00% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AMRS wins by $7175340620735.02M in total portfolio value
10 years
AMRS
AMRS
● Live price
4000.00%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7175340620755.87M
Annual income
$6,839,006,593,197,835,000.00
Full AMRS calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — AMRS vs GBDC

📍 AMRS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAMRSGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AMRS + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AMRS pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AMRS
Annual income on $10K today (after 15% tax)
$340,000.00/yr
After 10yr DRIP, annual income (after tax)
$5,813,155,604,218,160,000.00/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, AMRS beats the other by $5,813,155,604,204,177,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AMRS + GBDC for your $10,000?

AMRS: 50%GBDC: 50%
100% GBDC50/50100% AMRS
Portfolio after 10yr
$3587670310388.36M
Annual income
$3,419,503,296,607,143,000.00/yr
Blended yield
95.31%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AMRS right now

AMRS
Analyst Ratings
9
Buy
9
Hold
2
Sell
Consensus: Buy
Altman Z
-9.1
Piotroski
2/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AMRS buys
0
GBDC buys
0
No recent congressional trades found for AMRS or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAMRSGBDC
Forward yield4000.00%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$7175340620755.87M$20.85M
Annual income after 10y$6,839,006,593,197,835,000.00$16,450,733.83
Total dividends collected$7152397773804.84M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: AMRS vs GBDC ($10,000, DRIP)

YearAMRS PortfolioAMRS Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$410,700$400,000.00$12,492$1,791.70+$398.2KAMRS
2$15,792,720$15,353,271.03$16,527$3,160.58+$15.78MAMRS
3$568,657,142$551,758,931.89$23,588$5,904.90+$568.63MAMRS
4$19,176,207,860$18,567,744,718.20$37,141$11,901.65+$19176.17MAMRS
5$605,696,028,890$585,177,486,479.73$66,205$26,463.38+$605695.96MAMRS
6$17,922,210,653,594$17,274,115,902,681.27$137,452$66,612.65+$17922210.52MAMRS
7$496,869,793,504,300$477,693,028,104,954.00$342,372$195,298.53+$496869793.16MAMRS
8$12,908,672,105,251,704$12,377,021,426,202,104.00$1,053,292$686,954.33+$12908672104.20MAMRS
9$314,330,866,876,668,540$300,518,587,724,049,200.00$4,111,439$2,984,416.95+$314330866872.56MAMRS
10$7,175,340,620,755,871,000$6,839,006,593,197,835,000.00$20,849,974$16,450,733.83+$7175340620735.02MAMRS

AMRS vs GBDC: Complete Analysis 2026

AMRSStock

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

Full AMRS Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this AMRS vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AMRS vs SCHDAMRS vs JEPIAMRS vs OAMRS vs KOAMRS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.